Payload Information

General Information of This Payload
Payload ID
PAY0QAMZK
Name
Irinotecan
Synonyms
Irinotecan; 97682-44-5; (+)-Irinotecan; Camptosar; Irinotecanum; Biotecan; Irinotecanum [INN-Latin]; Irinotecan lactone; Campto; Irinophore C; Irinotecan mylan; Irinotecan [INN:BAN]; CPT-11; Irinotecan Free base; (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate; Biotecan (TN); Irinotecan (INN); HSDB 7607; CHEMBL481; NSC-728073; CHEBI:80630; irinotecan liposome; C33H38N4O6; 97682-44-5 (Free base); (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; UNII-7673326042; Camptosar (TN); IRINOTECAN [INN]; Campto (TN); irinotecan liposome injection; 1,4'-Bipiperidine-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14- tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester; CPT-11 hydrochloride;Camptothecin 11 hydrochloride; IRINOTECAN, CPT-11; (1,4'-Bipiperidine)-1'-carboxylic acid, 4,11-diethyl-3,4,12-14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, (S)-; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; MFCD00866307; 1,4'-bipiperidine-1'-carboxylic acid (s)-4,11-diethyl-3,4,12,14- tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester; IRINOTECAN [MI]; IRINOTECAN [HSDB]; IRINOTECAN [VANDF]; D07HOB; SCHEMBL4034; IRINOTECAN [WHO-DD]; IRINOTECAN; CPT-11; BSPBio_002346; Irinotecan (TOPO1 inhibitor); GTPL6823; DTXSID1041051; AMY4227; 1u65; UWKQSNNFCGGAFS-XIFFEERXSA-N; BCP02860; BDBM50128267; NSC728073; s1198; AKOS015894969; AB07527; AC-7469; BCP9000793; CS-1138; CS-O-01663; DB00762; NSC 728073; Camptosar, Campto, CPT-11, Irinotecan; NCGC00178697-02; NCGC00178697-05; AS-14323; HY-16562; LS-44589; NCI60_005051; D08086; EN300-708800; AB00698464-07; AB00698464-09; AB00698464-10; AB00698464-11; AB00698464_12; AB00698464_13; AB00698464_14; A845740; Q412197; BRD-K08547377-003-02-4; (diethyl-hydroxy-dioxo-[?]yl) 4-(1-piperidyl)piperidine-1-carboxylate; 3-tert-Butoxycarbonylamino-5-(4-fluorophenyl)thiophene-2-carboxylicacid; 2-methoxy-5-[2-(3-sulfophenyl)-5-(4-sulfophenyl)pyrylium-4-yl]benzenesulfonic acid; (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate; (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3'',4'':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4''-BIPIPERIDINE-1''-CARBOXYLATE; (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate; (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl[1,4'-bipiperidine]-1'-carboxylate; [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate; [1,4'']bipiperidinyl-1''-carboxylic acid (S)-4,11-diethyl-4-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-9-yl ester; [1,4'']Bipiperidinyl-1''-carboxylic acid 4,11-diethyl-4-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-9-yl ester
   Click to Show/Hide
Target(s) DNA topoisomerase 1 (TOP1)
 Target Info 
Structure
Formula
C33H38N4O6
Isosmiles
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
PubChem CID
60838
InChI
InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
InChIKey
UWKQSNNFCGGAFS-XIFFEERXSA-N
IUPAC Name
[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
Pharmaceutical Properties
Molecule Weight
586.7
Polar area
113
Complexity
1200
xlogp Value
3
Heavy Count
43
Rot Bonds
5
Hbond acc
8
Hbond Donor
1
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Half Maximal Inhibitory Concentration (IC50) 0.01 nM
NCI-H446 cells
Lung small cell carcinoma
CVCL_1562 
[1]
Half Maximal Inhibitory Concentration (IC50) 0.13 nM
NCI-H446 cells
Lung small cell carcinoma
CVCL_1562 
[1]
Half Maximal Inhibitory Concentration (IC50) 0.15 nM
NCI-H446 cells
Lung small cell carcinoma
CVCL_1562 
[1]
Half Maximal Inhibitory Concentration (IC50) 1 nM
Bone marrow cells
Normal
Undisclosed [2]
Half Maximal Inhibitory Concentration (IC50) 10 nM
MES-SA cells
Uterine sarcoma
CVCL_1404 
[2]
Half Maximal Inhibitory Concentration (IC50) 100 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[2]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >1000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[3]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >1000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[3]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >1000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[3]
Half Maximal Inhibitory Concentration (IC50) 1000 nM
NB-4 cells
Promyelocytic leukemia
CVCL_0005 
[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >10000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[5]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >10000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[6]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
JeKo-1 cells
Mantle cell lymphoma
CVCL_1865 
[4]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
KM-H2 cells
Hodgkin lymphoma
CVCL_1330 
[4]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
L-428 cells
Hodgkin lymphoma
CVCL_1361 
[4]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
OCI-Ly3 cells
Diffuse large B-cell lymphoma
CVCL_8800 
[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >10000 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[5]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >10000 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[6]
Half Maximal Cell Growth Inhibitory Concentration (GI50) >10000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[6]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
DG-75 cells
Burkitt lymphoma
CVCL_0244 
[4]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[7]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[7]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
SW1990 cells
Pancreatic adenocarcinoma
CVCL_1723 
[7]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
HEK293 cells
Normal
CVCL_0045 
[7]
Half Maximal Inhibitory Concentration (IC50) 110 nM
Bone marrow cells
Normal
Undisclosed [2]
Half Maximal Inhibitory Concentration (IC50) 1121 nM
Capan-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0237 
[8]
Half Maximal Inhibitory Concentration (IC50) 11300 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[9]
Half Maximal Inhibitory Concentration (IC50) 11300 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[10]
Half Maximal Inhibitory Concentration (IC50) 11320 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[11]
Half Maximal Inhibitory Concentration (IC50) 11510 nM
NCI-H146 cells
Small cell carcinoma
CVCL_1473 
[12]
Half Maximal Inhibitory Concentration (IC50) 1160 nM
LS174T cells
Colon adenocarcinoma
CVCL_1384 
[13]
Half Maximal Inhibitory Concentration (IC50) <120 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[14]
Half Maximal Inhibitory Concentration (IC50) <120 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[14]
Half Maximal Inhibitory Concentration (IC50) 1200 nM
T84 cells
Colon adenocarcinoma
CVCL_0555 
[15]
Half Maximal Inhibitory Concentration (IC50) 1200 nM
L1210 cells
Lymphoblastic leukemia
CVCL_0382 
[16]
Half Maximal Inhibitory Concentration (IC50) 12030 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[12]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 12200 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[17]
Half Maximal Inhibitory Concentration (IC50) 12250 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[18]
Half Maximal Inhibitory Concentration (IC50) 12300 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[19]
Half Maximal Inhibitory Concentration (IC50) 12400 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[14]
Half Maximal Inhibitory Concentration (IC50) 1305 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[8]
Half Maximal Inhibitory Concentration (IC50) 13130 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[14]
Half Maximal Inhibitory Concentration (IC50) 13200 nM
CCD-841CoN cells
Normal
CVCL_2871 
[20]
Half Maximal Inhibitory Concentration (IC50) 1329 nM
MIA PaCa-2 cells (MSLN expression)
Pancreatic ductal adenocarcinoma
CVCL_0428 
[8]
Half Maximal Inhibitory Concentration (IC50) 13630 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[18]
Half Maximal Inhibitory Concentration (IC50) 13900 nM
WiDr cells
Colon adenocarcinoma
CVCL_2760 
[21]
Half Maximal Inhibitory Concentration (IC50) 1400 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[22]
Half Maximal Inhibitory Concentration (IC50) 1400 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[23]
Half Maximal Inhibitory Concentration (IC50) 1400 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[24]
Half Maximal Inhibitory Concentration (IC50) 14100 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[25]
Half Maximal Inhibitory Concentration (IC50) 14210 nM
U2OS cells
Osteosarcoma
CVCL_0042 
[18]
Half Maximal Inhibitory Concentration (IC50) 14282 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[26]
Half Maximal Inhibitory Concentration (IC50) 15 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[2]
Half Maximal Inhibitory Concentration (IC50) 1500 nM
Capan-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0237 
[4]
Half Maximal Inhibitory Concentration (IC50) 15220 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[14]
Half Maximal Inhibitory Concentration (IC50) 15400 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[14]
Half Maximal Inhibitory Concentration (IC50) 1556 nM
Farage cells
Normal
CVCL_0214 
[27]
Half Maximal Inhibitory Concentration (IC50) 15560 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[11]
Half Maximal Inhibitory Concentration (IC50) 1557 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[8]
Half Maximal Inhibitory Concentration (IC50) 15600 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[9]
Half Maximal Inhibitory Concentration (IC50) 15600 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[10]
Half Maximal Inhibitory Concentration (IC50) 160 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[14]
Half Maximal Inhibitory Concentration (IC50) 1633.47 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[28]
Half Maximal Inhibitory Concentration (IC50) 16530 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[18]
Half Maximal Inhibitory Concentration (IC50) 1670 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[14]
Half Maximal Inhibitory Concentration (IC50) 17000 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[29]
Half Maximal Inhibitory Concentration (IC50) 17403 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[30]
Half Maximal Inhibitory Concentration (IC50) 18000 nM
ZR-75-30 cells
Breast carcinoma
CVCL_1661 
[31]
Half Maximal Inhibitory Concentration (IC50) 18090 nM
MG-63 cells
Osteosarcoma
CVCL_0426 
[18]
Half Maximal Inhibitory Concentration (IC50) 1827 nM
HEK293 cells
Normal
CVCL_0045 
[27]
Half Maximal Inhibitory Concentration (IC50) 18500 nM
CCD-18Co cells
Normal
CVCL_2379 
[20]
Half Maximal Inhibitory Concentration (IC50) 18600 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[32]
Half Maximal Inhibitory Concentration (IC50) 1880.93 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[28]
Half Maximal Inhibitory Concentration (IC50) 18810 nM
NCI-H2170 cells
Lung squamous cell carcinoma
CVCL_1535 
[12]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1900 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[33]
Half Maximal Inhibitory Concentration (IC50) 1900 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[15]
Half Maximal Inhibitory Concentration (IC50) 19710 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[12]
Half Maximal Inhibitory Concentration (IC50) 1980 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[14]
Half Maximal Inhibitory Concentration (IC50) 200 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[2]
Half Maximal Inhibitory Concentration (IC50) 200 nM
Malme-3M cells
Melanoma
CVCL_1438 
[2]
Half Maximal Inhibitory Concentration (IC50) 2000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[34]
Half Maximal Inhibitory Concentration (IC50) 2000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[19]
Half Maximal Inhibitory Concentration (IC50) 20000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[31]
Half Maximal Inhibitory Concentration (IC50) 20100 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[32]
Half Maximal Inhibitory Concentration (IC50) 20800 nM
HEK293 cells
Normal
CVCL_0045 
[35]
Half Maximal Inhibitory Concentration (IC50) 2100 nM
HEK293 cells
Normal
CVCL_0045 
[35]
Half Maximal Inhibitory Concentration (IC50) 21490 nM
NCI-H1975 cells
Lung adenocarcinoma
CVCL_1511 
[12]
Half Maximal Inhibitory Concentration (IC50) 22 nM
NCI-H69 cells
Small cell lung carcinoma
CVCL_1579 
[2]
Half Maximal Inhibitory Concentration (IC50) 22 nM
MES-SA/Dx5 cells
Uterine sarcoma
CVCL_2598 
[2]
Half Maximal Inhibitory Concentration (IC50) 220 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[2]
Half Maximal Inhibitory Concentration (IC50) 220 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[14]
Half Maximal Inhibitory Concentration (IC50) 2250 nM
786-O cells
Renal cell carcinoma
CVCL_1051 
[12]
Half Maximal Inhibitory Concentration (IC50) 2260 nM
NCI-H82 cells
Lung small cell carcinoma
CVCL_1591 
[12]
Half Maximal Inhibitory Concentration (IC50) 2400 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[4]
Half Maximal Inhibitory Concentration (IC50) 250 nM
H69AR cells
Lung small cell carcinoma
CVCL_3513 
[2]
Half Maximal Inhibitory Concentration (IC50) >250000 nM
U-87MG ATCC cells
Glioblastoma
CVCL_0022 
[36]
Half Maximal Inhibitory Concentration (IC50) 25100 nM
DLD-1 cells
Colon adenocarcinoma
CVCL_0248 
[37]
Half Maximal Inhibitory Concentration (IC50) 25400 nM
Mononuclear cells
Normal
Undisclosed [38]
Half Maximal Inhibitory Concentration (IC50) 26550 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[18]
Half Maximal Inhibitory Concentration (IC50) 26690 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[25]
Half Maximal Inhibitory Concentration (IC50) 27 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[2]
Half Maximal Inhibitory Concentration (IC50) 270 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[14]
Half Maximal Inhibitory Concentration (IC50) 2700 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[20]
Half Maximal Inhibitory Concentration (IC50) 2700 nM
HEK293 cells
Normal
CVCL_0045 
[35]
Half Maximal Inhibitory Concentration (IC50) 2800 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[4]
Half Maximal Inhibitory Concentration (IC50) 2810 nM
NCI-H211 cells
Small cell carcinoma
CVCL_1529 
[12]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3 nM
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[39]
Half Maximal Inhibitory Concentration (IC50) 30 nM
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
CVCL_1304 
[2]
Half Maximal Inhibitory Concentration (IC50) 3171 nM
Sf9 cells
Normal
CVCL_0549 
[27]
Half Maximal Inhibitory Concentration (IC50) 32 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[40]
Half Maximal Inhibitory Concentration (IC50) 32 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[40]
Half Maximal Inhibitory Concentration (IC50) 32 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[40]
Half Maximal Inhibitory Concentration (IC50) 34070 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[34]
Half Maximal Inhibitory Concentration (IC50) 3550 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[41]
Half Maximal Inhibitory Concentration (IC50) 36160 nM
NCI-H520 cells
Lung squamous cell carcinoma
CVCL_1566 
[12]
Half Maximal Inhibitory Concentration (IC50) 3800 nM
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[4]
Half Maximal Inhibitory Concentration (IC50) 3800 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[20]
Half Maximal Inhibitory Concentration (IC50) 38100 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[14]
Half Maximal Inhibitory Concentration (IC50) 38100 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[14]
Half Maximal Inhibitory Concentration (IC50) 39200 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[14]
Half Maximal Inhibitory Concentration (IC50) 3960 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[41]
Half Maximal Inhibitory Concentration (IC50) 39670 nM
NCI-H1650 cells
Lung adenocarcinoma
CVCL_1483 
[12]
Half Maximal Inhibitory Concentration (IC50) 4 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[2]
Half Maximal Inhibitory Concentration (IC50) 4 nM
A375 cells
Amelanotic melanoma
CVCL_0132 
[2]
Half Maximal Inhibitory Concentration (IC50) 4.4 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[42]
Half Maximal Inhibitory Concentration (IC50) 4000 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[4]
Half Maximal Inhibitory Concentration (IC50) 40000 nM
KB-V1 cells
Cervical carcinoma
CVCL_2089 
[43]
Half Maximal Inhibitory Concentration (IC50) 4100 nM
A-431 cells
Skin squamous cell carcinoma
CVCL_0037 
[4]
Half Maximal Inhibitory Concentration (IC50) 4240 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[25]
Half Maximal Inhibitory Concentration (IC50) 4250 nM
NCI-H226 cells
Pleural epithelioid mesothelioma
CVCL_1544 
[12]
Half Maximal Inhibitory Concentration (IC50) 4300 nM
MDCK-II cells
Normal
CVCL_0424 
[35]
Half Maximal Inhibitory Concentration (IC50) 4400 nM
U2932 cells
Lymphoma
CVCL_1896 
[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4730 nM
Hep 3B2.1-7 cells
Childhood hepatocellular carcinoma
CVCL_0326 
[5]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4730 nM
Hep 3B2.1-7 cells
Childhood hepatocellular carcinoma
CVCL_0326 
[6]
Half Maximal Inhibitory Concentration (IC50) 4800 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[4]
Half Maximal Inhibitory Concentration (IC50) 490 nM
NCI-H526 cells
Lung small cell carcinoma
CVCL_1569 
[12]
Half Maximal Inhibitory Concentration (IC50) 498 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[8]
Half Maximal Inhibitory Concentration (IC50) 5.1 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[42]
Half Maximal Inhibitory Concentration (IC50) 500 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[22]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[17]
Half Maximal Inhibitory Concentration (IC50) 5150 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[12]
Half Maximal Inhibitory Concentration (IC50) 5237.6 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[26]
Half Maximal Inhibitory Concentration (IC50) 570 nM
RPMI-8402 cells
T acute lymphoblastic leukemia
CVCL_1667 
[44]
Half Maximal Inhibitory Concentration (IC50) 5800 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5940 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[5]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5940 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[6]
Half Maximal Inhibitory Concentration (IC50) 6.9 nM
T84 cells
Colon adenocarcinoma
CVCL_0555 
[42]
Half Maximal Inhibitory Concentration (IC50) 600 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[20]
Half Maximal Inhibitory Concentration (IC50) 600 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[14]
Half Maximal Inhibitory Concentration (IC50) 6200 nM
RKO cells
Colon carcinoma
CVCL_0504 
[19]
Half Maximal Inhibitory Concentration (IC50) 6300 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[31]
Half Maximal Inhibitory Concentration (IC50) 6300 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[32]
Half Maximal Inhibitory Concentration (IC50) 6314.3 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[26]
Half Maximal Inhibitory Concentration (IC50) 6400 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[29]
Half Maximal Inhibitory Concentration (IC50) 6528 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[30]
Half Maximal Inhibitory Concentration (IC50) 680 nM
KB 3-1 cells
Cervical epithelial carcinoma
CVCL_2088 
[43]
Half Maximal Inhibitory Concentration (IC50) 6850 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[25]
Half Maximal Inhibitory Concentration (IC50) 700 nM
RKO cells
Colon carcinoma
CVCL_0504 
[20]
Half Maximal Inhibitory Concentration (IC50) 700 nM
LS174T cells
Colon adenocarcinoma
CVCL_1384 
[20]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7100 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[17]
Half Maximal Inhibitory Concentration (IC50) 7200 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[14]
Half Maximal Inhibitory Concentration (IC50) 7400 nM
KBH5.0 cells
Endocervical adenocarcinoma
CVCL_D644 
[43]
Half Maximal Inhibitory Concentration (IC50) 74600 nM
HEK293 cells
Normal
CVCL_0045 
[35]
Half Maximal Inhibitory Concentration (IC50) 7530 nM
H3347 cells
Colon carcinoma
CVCL_LG07 
[37]
Half Maximal Inhibitory Concentration (IC50) 75300 nM
Ovarian cancer cells
Ovarian cancer
Undisclosed [38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 77530 nM
MRC5 cells
Normal
CVCL_0440 
[5]
Half Maximal Inhibitory Concentration (IC50) 78600 nM
HEK293 cells
Normal
CVCL_0045 
[35]
Half Maximal Inhibitory Concentration (IC50) 7900 nM
HEK293 cells
Normal
CVCL_0045 
[35]
Half Maximal Inhibitory Concentration (IC50) 7900 nM
HEK293 cells
Normal
CVCL_0045 
[35]
Half Maximal Inhibitory Concentration (IC50) 7990 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[9]
Half Maximal Inhibitory Concentration (IC50) 7990 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[11]
Half Maximal Inhibitory Concentration (IC50) 7990 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[10]
Half Maximal Inhibitory Concentration (IC50) 800 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[22]
Half Maximal Inhibitory Concentration (IC50) 800 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[15]
Half Maximal Inhibitory Concentration (IC50) 800 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[23]
Half Maximal Inhibitory Concentration (IC50) 800 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[24]
Half Maximal Inhibitory Concentration (IC50) 82750 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[37]
Half Maximal Inhibitory Concentration (IC50) 8300 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[9]
Half Maximal Inhibitory Concentration (IC50) 8300 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[10]
Half Maximal Inhibitory Concentration (IC50) 8310 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[11]
Half Maximal Inhibitory Concentration (IC50) 8500 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[19]
Half Maximal Inhibitory Concentration (IC50) 8800 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[29]
Half Maximal Inhibitory Concentration (IC50) 9 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[2]
Half Maximal Inhibitory Concentration (IC50) 900 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[22]
Half Maximal Inhibitory Concentration (IC50) 900 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[15]
Half Maximal Inhibitory Concentration (IC50) 9015 nM
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[30]
Half Maximal Inhibitory Concentration (IC50) 90250 nM
CCD-841CoN cells
Normal
CVCL_2871 
[25]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9170 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[6]
Half Maximal Inhibitory Concentration (IC50) 9300 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[45]
Half Maximal Inhibitory Concentration (IC50) 9300 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[46]
Half Maximal Inhibitory Concentration (IC50) 9480 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[45]
Half Maximal Inhibitory Concentration (IC50) 9480 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[47]
Half Maximal Inhibitory Concentration (IC50) 9500 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[46]
Half Maximal Inhibitory Concentration (IC50) 9500 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[48]
Half Maximal Inhibitory Concentration (IC50) 9700 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[48]
Half Maximal Inhibitory Concentration (IC50) 9790 nM
NCI-H1417 cells
Lung small cell carcinoma
CVCL_1469 
[12]
Half Maximal Inhibitory Concentration (IC50) 9800 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[46]
Half Maximal Inhibitory Concentration (IC50) 9828 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[47]
Half Maximal Inhibitory Concentration (IC50) 9830 nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
CVCL_0372 
[45]
Half Maximal Inhibitory Concentration (IC50) 9830 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[14]
Each Antibody-drug Conjugate Related to This Payload
References
Ref 1 Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo. Eur J Med Chem. 2022 Nov 5;241:114610. doi: 10.1016/j.ejmech.2022.114610. Epub 2022 Jul 20.
Ref 2 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. J Med Chem. 2011 Mar 24;54(6):1715-23. doi: 10.1021/jm101354u. Epub 2011 Feb 22.
Ref 3 Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives. Bioorg Med Chem. 2007 Jun 15;15(12):4237-46. doi: 10.1016/j.bmc.2007.03.067. Epub 2007 Mar 25.
Ref 4 Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors. Eur J Med Chem. 2018 Jan 1;143:2005-2014. doi: 10.1016/j.ejmech.2017.11.021. Epub 2017 Nov 8.
Ref 5 Synthesis and antiproliferative evaluation of 6-arylindeno[1,2-c]quinoline derivatives. Bioorg Med Chem. 2009 Nov 1;17(21):7465-76. doi: 10.1016/j.bmc.2009.09.021. Epub 2009 Sep 16.
Ref 6 Synthesis and antiproliferative evaluation of 6-aryl-11-iminoindeno[1,2-c]quinoline derivatives. Bioorg Med Chem. 2011 Dec 15;19(24):7653-63. doi: 10.1016/j.bmc.2011.10.014. Epub 2011 Oct 20.
Ref 7 Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Sep 15;202:112509. doi: 10.1016/j.ejmech.2020.112509. Epub 2020 Jun 30.
Ref 8 Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor-SN38 Conjugates for Targeted Drug Accumulation. J Med Chem. 2020 May 28;63(10):5421-5441. doi: 10.1021/acs.jmedchem.0c00305. Epub 2020 May 11.
Ref 9 Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1750-1753. doi: 10.1016/j.bmcl.2017.02.066. Epub 2017 Feb 28.
Ref 10 Design, semisynthesis and potent cytotoxic activity of novel 10-fluorocamptothecin derivatives. Bioorg Med Chem Lett. 2017 Oct 15;27(20):4694-4697. doi: 10.1016/j.bmcl.2017.09.012. Epub 2017 Sep 8.
Ref 11 Design, synthesis, and cytotoxic activity of novel 7-substituted camptothecin derivatives incorporating piperazinyl-sulfonylamidine moieties. Bioorg Med Chem Lett. 2017 Sep 1;27(17):3959-3962. doi: 10.1016/j.bmcl.2017.07.078. Epub 2017 Jul 29.
Ref 12 Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[g]pyrrolo[2,1-a]phthalazine Hybrids That Inhibit Angiogenesis and Induce DNA Cross-Links. J Med Chem. 2021 Sep 9;64(17):12469-12486. doi: 10.1021/acs.jmedchem.0c01733. Epub 2021 Aug 30.
Ref 13 In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorg Med Chem. 2008 Jul 1;16(13):6601-10. doi: 10.1016/j.bmc.2008.05.022. Epub 2008 May 10.
Ref 14 Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study. Eur J Med Chem. 2022 Apr 5;233:114196. doi: 10.1016/j.ejmech.2022.114196. Epub 2022 Feb 23.
Ref 15 Amorfrutin C Induces Apoptosis and Inhibits Proliferation in Colon Cancer Cells through Targeting Mitochondria. J Nat Prod. 2016 Jan 22;79(1):2-12. doi: 10.1021/acs.jnatprod.5b00072. Epub 2016 Jan 5.
Ref 16 Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem. 1991 Jan;34(1):98-107. doi: 10.1021/jm00105a017.
Ref 17 New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. J Med Chem. 2012 Sep 13;55(17):7593-613. doi: 10.1021/jm300605m. Epub 2012 Aug 22.
Ref 18 Synthesis, mechanisms of action, and toxicity of novel aminophosphonates derivatives conjugated irinotecan in?vitro and in?vivo as potent antitumor agents. Eur J Med Chem. 2020 Mar 1;189:112067. doi: 10.1016/j.ejmech.2020.112067. Epub 2020 Jan 14.
Ref 19 Antitumor Activity of Americanin A Isolated from the Seeds of Phytolacca americana by Regulating the ATM/ATR Signaling Pathway and the Skp2-p27 Axis in Human Colon Cancer Cells. J Nat Prod. 2015 Dec 24;78(12):2983-93. doi: 10.1021/acs.jnatprod.5b00743. Epub 2015 Nov 23.
Ref 20 Antitumor Activity of Rutaecarpine in Human Colorectal Cancer Cells by Suppression of Wnt/-Catenin Signaling. J Nat Prod. 2022 May 27;85(5):1407-1418. doi: 10.1021/acs.jnatprod.2c00224. Epub 2022 May 11.
Ref 21 Design, synthesis, and antitumor activity evaluation of steroidal oximes. Bioorg Med Chem. 2021 Sep 15;46:116360. doi: 10.1016/j.bmc.2021.116360. Epub 2021 Aug 8.
Ref 22 Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery of the Effective Components of a Traditional Herbal Medicine. J Nat Prod. 2016 Feb 26;79(2):281-92. doi: 10.1021/acs.jnatprod.5b00877. Epub 2016 Feb 3.
Ref 23 Antcamphorols A-K, Cytotoxic and ROS Scavenging Triterpenoids from Antrodia camphorata. J Nat Prod. 2020 Jan 24;83(1):45-54. doi: 10.1021/acs.jnatprod.9b00580. Epub 2019 Dec 31.
Ref 24 Chemical modifications of ergostane-type triterpenoids from Antrodia camphorata and their cytotoxic activities. Bioorg Med Chem Lett. 2021 Jul 1;43:128066. doi: 10.1016/j.bmcl.2021.128066. Epub 2021 Apr 26.
Ref 25 New camptothecin derivatives for generalized oncological chemotherapy: Synthesis, stereochemistry and biology. Bioorg Med Chem Lett. 2021 Aug 15;46:128146. doi: 10.1016/j.bmcl.2021.128146. Epub 2021 May 25.
Ref 26 Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin. Eur J Med Chem. 2020 Feb 1;187:111971. doi: 10.1016/j.ejmech.2019.111971. Epub 2019 Dec 13.
Ref 27 DrugMatrix in vitro pharmacology data.
Ref 28 A series of camptothecin prodrugs exhibit HDAC inhibition activity. Bioorg Med Chem. 2018 Sep 1;26(16):4706-4715. doi: 10.1016/j.bmc.2018.08.008. Epub 2018 Aug 4.
Ref 29 Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents. J Med Chem. 2010 Nov 11;53(21):7521-31. doi: 10.1021/jm100387d.
Ref 30 New homocamptothecins: synthesis, antitumor activity, and molecular modeling. Bioorg Med Chem. 2008 Feb 1;16(3):1493-510. doi: 10.1016/j.bmc.2007.10.046. Epub 2007 Oct 22.
Ref 31 Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors. Bioorg Med Chem Lett. 2017 May 1;27(9):1929-1933. doi: 10.1016/j.bmcl.2017.03.039. Epub 2017 Mar 18.
Ref 32 Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents. J Med Chem. 2015 Aug 27;58(16):6678-96. doi: 10.1021/acs.jmedchem.5b00910. Epub 2015 Aug 19.
Ref 33 Injury-induced biosynthesis of methyl-branched polyene pigments in a white-rotting basidiomycete. J Nat Prod. 2014 Dec 26;77(12):2658-63. doi: 10.1021/np500552a. Epub 2014 Nov 24.
Ref 34 Recent advances in combretastatin A-4 codrugs for cancer therapy. Eur J Med Chem. 2022 Nov 5;241:114660. doi: 10.1016/j.ejmech.2022.114660. Epub 2022 Aug 9.
Ref 35 Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013 Feb 14;56(3):781-795. doi: 10.1021/jm301302s. Epub 2013 Jan 22.
Ref 36 Discovery of mitochondria-targeting berberine derivatives as the inhibitors of proliferation, invasion and migration against rat C6 and human U87 glioma cells. Medchemcomm. 2015;6(1):164-173.
Ref 37 Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach. Eur J Med Chem. 2014 Apr 9;76:155-69. doi: 10.1016/j.ejmech.2014.02.018. Epub 2014 Feb 11.
Ref 38 Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art. J Med Chem. 2022 Sep 8;65(17):11415-11432. doi: 10.1021/acs.jmedchem.2c00573. Epub 2022 Aug 26.
Ref 39 Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies. J Med Chem. 2007 Sep 6;50(18):4340-50. doi: 10.1021/jm061288r. Epub 2007 Aug 14.
Ref 40 Quinolone hybrids and their anti-cancer activities: An overview. Eur J Med Chem. 2019 Mar 1;165:59-79. doi: 10.1016/j.ejmech.2019.01.017. Epub 2019 Jan 11.
Ref 41 Multigram scale synthesis of polycyclic lactones and evaluation of antitumor and other biological properties. Eur J Med Chem. 2020 Jan 1;185:111807. doi: 10.1016/j.ejmech.2019.111807. Epub 2019 Oct 23.
Ref 42 Neothalfine, a potent natural anti-tumor agent against metastatic colorectal cancer and its primary mechanism. Bioorg Med Chem. 2021 Jan 1;29:115849. doi: 10.1016/j.bmc.2020.115849. Epub 2020 Nov 8.
Ref 43 11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents. Bioorg Med Chem. 2008 Sep 15;16(18):8598-606. doi: 10.1016/j.bmc.2008.08.018. Epub 2008 Aug 7.
Ref 44 Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. J Med Chem. 2003 May 22;46(11):2254-7. doi: 10.1021/jm020498a.
Ref 45 Design and one-pot synthesis of new 7-acyl camptothecin derivatives as potent cytotoxic agents. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7659-61. doi: 10.1016/j.bmcl.2012.10.002. Epub 2012 Oct 11.
Ref 46 Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents. J Med Chem. 2014 Jul 24;57(14):6008-18. doi: 10.1021/jm5003588. Epub 2014 Jul 8.
Ref 47 Design, synthesis, cytotoxic activity and molecular docking studies of new 20(S)-sulfonylamidine camptothecin derivatives. Eur J Med Chem. 2016 Jun 10;115:109-20. doi: 10.1016/j.ejmech.2016.02.070. Epub 2016 Mar 3.
Ref 48 Design, synthesis and high antitumor potential of new unsymmetrical bisacridine derivatives towards human solid tumors, specifically pancreatic cancers and their unique ability to stabilize DNA G-quadruplexes. Eur J Med Chem. 2020 Oct 15;204:112599. doi: 10.1016/j.ejmech.2020.112599. Epub 2020 Jul 16.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.